Piramal Pharma与韩国IntoCell合作, 利用新的毒品连锁技术促进ADC的发展。 Piramal Pharma partners with South Korea’s IntoCell to boost ADC development using new drug-linker tech.

Piramal药物解决方案公司与南朝鲜生物技术IntoCell公司签署了一项不具约束力的协议,以扩大其抗体药物共产体(ADC)发展能力。 Piramal Pharma Solutions has signed a non-binding agreement with South Korean biotech IntoCell to expand its antibody-drug conjugate (ADC) development capabilities. 这一伙伴关系使Piramal能够提供IntoCell的专有药物连锁技术,包括OHPAS连接器和Duocarmycin和Nexatecan等有效载荷,加强ADCerateTM平台。 The partnership enables Piramal to offer IntoCell’s proprietary drug-linker technologies, including the OHPAS linker and payloads like Duocarmycin and Nexatecan, enhancing its ADCelerate™ platform. 作为回报,IntoCell获得了皮拉马尔全球发展和制造网络的接入。 In return, IntoCell gains access to Piramal’s global development and manufacturing network. 合作的目的是加快ADC的开发,改进门诊时间到门诊时间,支持先进的治疗方法。 The collaboration aims to accelerate ADC development, improve time-to-clinic timelines, and support advanced therapeutics.